Oral GLP-1 agonist, Satiety Pathways, and Stem Cell tx for T1D

from TT HealthWatch · host Christina Acosta

Program notes:0:40 Stem cells for type 1 diabetes1:40 None had hypoglycemia afterwards2:40 Autologous stem cells?3:20 Oral GLP-1 agonist4:20 Primary endpoint HbA1c reduction5:20 Weight loss modest6:20 Injectable GLP-1 plus an amylin analogue7:20 Both those with diabetes and those without8:20 No increased safety events8:40 Mental health hospitalizations in adolescents9:40 KID database10:40 Females accounting for increase11:40 67% of hospitalizations12:57 End

Episode metadata supplied by the publisher feed · Published Jun 27, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Oral GLP-1 agonist, Satiety Pathways, and Stem Cell tx for T1D

0:00 12:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TT HealthWatch?

This episode is 12 minutes long.

When was this TT HealthWatch episode published?

This episode was published on June 27, 2025.

Can I download this TT HealthWatch episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!